CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. - Wikidata - wikimedia - TriplyDB

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

http://www.wikidata.org/entity/Q35116847

about

Pancreatic cancer stem cell markers and exosomes - the incentive push Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer The role of CD44 in epithelial-mesenchymal transition and cancer development Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells Development of cancer-initiating cells and immortalized cells with genomic instability.Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association with high cellular proliferation and high concentrations of EGFR and CD44v5.SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression.Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.Over expression of hyaluronan promotes progression of HCC via CD44-mediated pyruvate kinase M2 nuclear translocation.Ionizing radiation promotes advanced malignant traits in nasopharyngeal carcinoma via activation of epithelial-mesenchymal transition and the cancer stem cell phenotype Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.The Role of CD44 in Disease Pathophysiology and Targeted Treatment.Opportunities and challenges of radiotherapy for treating cancer.Prostate cancer stem cells: from theory to practice.Prostate Cancer Stem Cells: Viewing Signaling Cascades at a Finer Resolution.Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance.Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis.Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts.CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence.CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells.Advances in prostate cancer research and treatment.Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.The CD44-Mediated Uptake of Hyaluronic Acid-Based Carriers in Macrophages.Intratumoral heterogeneity of CD44v6 in rectal cancer.The biology and role of CD44 in cancer progression: therapeutic implications.Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo

P2860

Q26741215-F7A973FE-F935-4D15-AF7A-B87D8F78B388 Q26742062-79CF0BD6-D700-446A-8259-F596DC10D5A4 Q26771509-6D90A60E-5380-44ED-9CA2-F380674821F1 Q26853543-200E2DC2-DA15-405C-9634-11AD4777AB89 Q28084610-9BC2182B-4602-4AF6-9E7A-4A801E1808E8 Q35205699-982CC371-F5EB-4F92-B1F0-5746ECF22786 Q35380267-A48C5136-6F33-4227-BE7A-19931D1E059A Q35562215-36B17592-CC0C-435F-8E38-6F14DE29A0EC Q36535407-BF625EC8-37CC-4E42-91FB-1830A185A06C Q36878785-92D2A977-5636-4CE1-8E97-2CB050DFA45B Q36983775-46634D89-7C20-4AEC-91DC-E81890FF23DE Q37615676-CCD136D4-61D6-4D9B-8BC9-C7360B210136 Q38466771-E92ED9B0-6E4D-4902-AA29-F14E9AE3CD86 Q38539957-11CCEA81-1337-482D-A601-095CD3D96211 Q38668605-69142F87-BB3B-437D-8F26-2BED39623531 Q38723375-41A97C59-904F-462C-8256-ADA30E287B6E Q38805489-5A12DBA9-11D5-4C3C-96F4-4E5074C9E62E Q38845190-1C8A72A8-E063-4483-81B9-57F55BCCDEB3 Q38872768-B225107A-52CF-467C-94FF-C1EAA5D63A3C Q38889921-56BB1232-8AF9-42C4-9A20-28DA15444712 Q41294963-47C9B4E3-BF2D-4231-A3B1-65E649C361F9 Q41849010-DBF88891-5801-4459-80C2-85B02CB25BC2 Q42084382-E0BBE49D-9379-435A-8E86-18D6FB5B6B6D Q42113453-52FCF81A-3E35-454A-815A-744D62D43273 Q43869209-744F0DEC-7CF0-44B8-8932-02B7992508D7 Q44262180-640CF929-1CE7-443E-BDD3-9E5F430841FC Q51251704-C67EAC9A-6771-4CC2-8FAD-52830DF713BC Q51554860-2F46BA38-7E5E-4B69-B72B-AC1548B44F60 Q54110894-618A0364-0864-4DA8-9007-217E246A17BC Q55309145-0F55EA18-7C1E-4477-8CA6-BE907C74C6C3 Q59136173-3DFC9F37-5607-4998-8E61-3CD7928BA10F

P2860

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

http://www.wikidata.org/entity/Q35116847

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

@ast

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

@en

type

label

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

@ast

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

@en

prefLabel

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

@ast

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

@en

P1433

Q35116847-F5A1D1F0-2176-47EF-84B0-B6DFAA17C8DE

P1476

Q35116847-48123198-D749-4CFA-B16A-59FB8CDDCACE

P2093

Q35116847-1ED3B837-3E92-4ABE-BFB2-724CC33F03F3

Q35116847-3DB12101-84DC-4B97-BDA2-F8A8653AC858

Q35116847-4724C62A-80B4-4F2C-A2EC-65F8A50E03E9

Q35116847-4EF1849D-0249-4F52-80E0-40196CB0ADEB

Q35116847-70855227-0ECD-4A64-89AB-E3C6AFFA2049

Q35116847-8178716B-E8F7-4AB0-B243-1D4D2E5562FA

Q35116847-97160DF7-F47C-41F0-B233-95C4C8EB2217

Q35116847-98ECCCE9-782B-4CAF-A389-9AFBCD98E1E8

Q35116847-C199117D-2A61-4829-8868-748820BFC9B8

Q35116847-CA0654B9-52D8-4D5F-B808-380F4A6EE347

P2860

Q35116847-07D2514F-60E1-4BE0-B2B8-32C24D4DDE1D

Q35116847-0A86F960-4D65-4045-B2E5-431AC81CCECC

Q35116847-0E629DC9-393C-4638-B132-EBAB2EB560D7

Q35116847-140CE4D7-7737-4C90-AA7B-86F51B3527BE

Q35116847-152BBCC8-11E0-428D-AD49-6121E1768AB6

Q35116847-211BB8EF-D72B-4582-B8C7-95DC4FFB92D0

Q35116847-24EC7BC4-0D2E-49F4-B55F-AE9E4AD121E1

Q35116847-2520BB9E-7C3D-4F6C-9219-BDFD2455E92E

Q35116847-27E894AD-163B-4BEE-ADFF-E171F3B20CB5

Q35116847-2E8B5451-A518-48D1-870A-DF85A081F997

P304

Q35116847-7ABB5B4F-085F-49F0-931F-21B361CDC9F6

P31

Q35116847-C656E0FD-7FEB-4B6B-A23C-D8C6207DA50C

P356

Q35116847-3A9176A5-6443-43E2-881E-C90F0C024572

P433

Q35116847-3BEB8B83-681C-4444-A214-9DBCB2532417

P478

Q35116847-A8095CEE-2CC5-478F-AE8A-20F425AE0AB2

P50

Q35116847-61C4B239-2B3C-4610-B76D-5A7BD35FBBE7

Q35116847-A979930A-376F-405F-8624-113217FFFE7F

P577

Q35116847-ED4C63B1-D00B-42BF-B843-60FEF1953AB3

P5875

Q35116847-DDC97B03-95BA-4FE7-9A69-0A90D3E65ECC

P698

Q35116847-5FE12787-27A1-4062-928B-CFAA2F186E76

P356

P1433

P1476

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

@en

P2093

Jing L Hao

http://www.w3.org/2001/XMLSchema#string

John H Kearsley

http://www.w3.org/2001/XMLSchema#string

Joseph Bucci

http://www.w3.org/2001/XMLSchema#string

Julia Beretov

http://www.w3.org/2001/XMLSchema#string

Lei Chang

http://www.w3.org/2001/XMLSchema#string

Paul J Cozzi

http://www.w3.org/2001/XMLSchema#string

Peter H Graham

http://www.w3.org/2001/XMLSchema#string

Sarah Shigdar

http://www.w3.org/2001/XMLSchema#string

Warick J Delprado

http://www.w3.org/2001/XMLSchema#string

Wei Duan

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

The basics of epithelial-mesenchymal transition

Prospective identification of tumorigenic breast cancer cells

Identification of pancreatic cancer stem cells

In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties

Stem cell origin of cancer and differentiation therapy.

P304

602-617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.22775

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260342893

http://www.w3.org/2001/XMLSchema#string

P698

24615685

http://www.w3.org/2001/XMLSchema#string